Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

Journal Articles

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

Blood (2016) 128 (22): 915.

https://doi.org/10.1182/blood.V128.22.915.915

Published: 2016

Journal Articles

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Hiroyuki Takamatsu, Ryoichi Murata, MD, Jianbiao Zheng, Martin Moorhead, Naoki Takezako, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1788.

https://doi.org/10.1182/blood.V126.23.1788.1788

Published: 2015

Journal Articles

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Rachel K Wee, Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1782.

https://doi.org/10.1182/blood.V126.23.1782.1782

Published: 2015

Journal Articles

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD, PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2014) 124 (21): 2003.

https://doi.org/10.1182/blood.V124.21.2003.2003

Published: 2014

Journal Articles

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

Blood (2014) 124 (21): 2105.

https://doi.org/10.1182/blood.V124.21.2105.2105

Published: 2014

Journal Articles

Next-Generation Sequencing Reveals Clonal Evolution at the Immunoglobulin Loci in Chronic Lymphocytic Leukemia

Jennifer R. Brown, Stacey M. Fernandes, Siddha Kasar, Kevin Hoang, Martin Moorhead, PhD, Victoria Carlton, Malek Faham, David B. Miklos, Aaron C. Logan

Blood (2014) 124 (21): 3302.

https://doi.org/10.1182/blood.V124.21.3302.3302

Published: 2014

Journal Articles

High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064)

Nina Wagner-Johnston, Jeannette Y. Lee, Sylvia Silver, Ariela Noy, Martha P. Mims, Francois Pepin, Martin Moorhead, PhD, Malek Faham, Richard F. Ambinder

Blood (2014) 124 (21): 1680.

https://doi.org/10.1182/blood.V124.21.1680.1680

Published: 2014

Journal Articles

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Blood (2014) 123 (20): 3073–3079.

https://doi.org/10.1182/blood-2014-01-550020

Published: 2014

Journal Articles

Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone

Blood (2013) 122 (21): 1902.

https://doi.org/10.1182/blood.V122.21.1902.1902

Published: 2013

Journal Articles

A Comparison Between Next-Generation Sequencing and ASO-qPCR For Minimal Residual Disease Detection In Multiple Myeloma: The Clinical Value In ASCT Setting

Hiroyuki Takamatsu, MD, PhD, Ryoichi Mura, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Terasaki Yasushi, MD, PhD, Yoshida Takashi, MD, PhD, Malek Faham, MD, PhD, Shinji Nakao, MD, PhD

Blood (2013) 122 (21): 1843.

https://doi.org/10.1182/blood.V122.21.1843.1843

Published: 2013

Journal Articles

Alloreactive T Cell Clonotypes Identified By In Vitro Mixed Lymphoid Reaction and High-Throughput Sequencing Exhibit Increased Frequency In Peripheral Blood Samples From Patients Following Allogeneic Hematopoietic Cell Transplantation For Chronic Lymphocytic Leukemia

Aaron C. Logan, MD, PhD, Mark R. Krampf, MS, Mark Klinger, PhD, Martin Moorhead, PhD, Jianbiao Zheng, PhD, Randall Armstrong, Malek Faham, MD, PhD, Kenneth I Weinberg, MD, David B. Miklos, MD, PhD

Blood (2013) 122 (21): 149.

https://doi.org/10.1182/blood.V122.21.149.149

Published: 2013

Journal Articles

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients

Joaquin Martinez-Lopez, MD, PhD, Mariateresa Fulciniti, PhD, Santiago Barrio, PhD, Victoria Carlton, PhD, Martin Moorhead, PhD, Juan Jose Lahuerta, MD, Kenneth C. Anderson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Herve Avet-loiseau, Malek Faham, MD, PhD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 401.

https://doi.org/10.1182/blood.V122.21.401.401

Published: 2013

Journal Articles

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

Malek Faham, Jianbiao Zheng, Martin Moorhead, Victoria E. H. Carlton, Patricia Stow, Elaine Coustan-Smith, Ching-Hon Pui, Dario Campana

Blood (2012) 120 (26): 5173–5180.

https://doi.org/10.1182/blood-2012-07-444042

Published: 2012

Includes: Supplemental data

Journal Articles

Clonosight: A Standardized Clinical Assay for Measurement of Minimal Residual Disease in Leukemias and Lymphomas

Thomas D. Willis, PhD, Tom Asbury, PhD, Victoria Carlton, PhD, Lei Fang, PhD, Mark Klinger, PhD, Martin Moorhead, PhD, Kaliprasad Pothuraju, MS, Li Weng, PhD, Jianbiao Zheng, PhD, Malek Faham, MD, PhD

Blood (2012) 120 (21): 1434.

https://doi.org/10.1182/blood.V120.21.1434.1434

Published: 2012

Journal Articles

Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort

Charles Gawad, MD, Michael J. Borowitz, MD, PhD, Gary V. Dahl, MD, Meenakshi Devidas, PhD, Malek Faham, MD, PhD, Martin Moorhead, PhD, Brent L. Wood, MD, PhD, Jianbiao Zheng, PhD, Mignon L. Loh, MD, Norman J. Lacayo, MD

Blood (2012) 120 (21): 1440.

https://doi.org/10.1182/blood.V120.21.1440.1440

Published: 2012

Journal Articles

Deep Sequencing Approach for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Malek Faham, MD, PhD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Victoria Carlton, Patricia Lee Stow, BA, MS, Elaine Coustan-Smith, MS, Ching-Hon Pui, MD, Dario Campana, MD, PhD

Blood (2012) 120 (21): 1388.

https://doi.org/10.1182/blood.V120.21.1388.1388

Published: 2012

Journal Articles

Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.

Aaron C. Logan, MD, PhD, Nikita Vashi, BS, Malek Faham, MD, PhD, Victoria Carlton, PhD, Ismael Buno, PhD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Mark Klinger, PhD, Tom Willis, PhD, Bing Zhang, MD, Amna Waqar, BS, James L. Zehnder, David B Miklos, MD, PhD

Blood (2012) 120 (21): 2512.

https://doi.org/10.1182/blood.V120.21.2512.2512

Published: 2012

Journal Articles

Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia.

Marian Harris, MD, Malek Faham, MD, PhD, Lei Fang, PhD, Martin Moorhead, PhD, Jianbiao Zheng, PhD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Kristen E. Stevenson, MS

Blood (2012) 120 (21): 2532.

https://doi.org/10.1182/blood.V120.21.2532.2532

Published: 2012

NARROW

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

Next-Generation Sequencing Reveals Clonal Evolution at the Immunoglobulin Loci in Chronic Lymphocytic Leukemia

High Frequency of Identical Lymphoma Clones Detected in Pre-Treatment Tumor and Plasma from Untreated Patients with HIV-Associated Lymphomas: Prospective Multicenter Trial of the AIDS Malignancy Consortium (AMC 064)

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Minimal Residual Disease (MRD) Detection By Deep Sequencing In Newly Diagnosed Multiple Myeloma Patients Treated With Carfilzomib, Lenalidomide and Dexamethasone

A Comparison Between Next-Generation Sequencing and ASO-qPCR For Minimal Residual Disease Detection In Multiple Myeloma: The Clinical Value In ASCT Setting

Alloreactive T Cell Clonotypes Identified By In Vitro Mixed Lymphoid Reaction and High-Throughput Sequencing Exhibit Increased Frequency In Peripheral Blood Samples From Patients Following Allogeneic Hematopoietic Cell Transplantation For Chronic Lymphocytic Leukemia

Deep Sequencing Reveals Oligoclonality At The Immunoglobulin Locus In Multiple Myeloma Patients

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

Clonosight: A Standardized Clinical Assay for Measurement of Minimal Residual Disease in Leukemias and Lymphomas

Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort

Deep Sequencing Approach for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia Using High-Throughput Sequencing of Multiple Immunoreceptor Genes Predicts Relapse and Survival After Allogeneic Hematopoietic Cell Transplantation.

Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only